Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
230 hedge funds and large institutions have $3.95B invested in Mirati Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 110 increasing their positions, 60 reducing their positions, and 55 closing their positions.
298% more call options, than puts
Call options by funds: $95.4M | Put options by funds: $24M
83% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 60
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
9% less funds holding
Funds holding: 253 → 230 (-23)
16% less capital invested
Capital invested by funds: $4.7B → $3.95B (-$749M)
35% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 55
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$147M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$50.8M |
| 3 |
Morgan Stanley
New York
|
+$49.6M |
| 4 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$46.5M |
| 5 |
AC
Armistice Capital
New York
|
+$43.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$115M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$60.4M |
| 3 |
Holocene Advisors
New York
|
-$53.9M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$41.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$37.7M |
MRTX Hedge Fund Activity: Q2 2022 in Review
230 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q2 2022, worth a combined $3.95B — down 16% from $4.7B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of MRTX and 36 opened new positions — a net loss of 19 holders — while 60 trimmed existing stakes and 110 added.
The largest buyer was Goldman Sachs, adding an estimated $147M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $115M sold.
- 230 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q2 2022, down from 253 in Q1 2022.
- Funds reported $3.95B of Mirati Therapeutics, Inc. Common Stock stock for Q2 2022, down 16% quarter-over-quarter.
- 36 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q2 2022 and 55 closed out, a net change of -19 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q2 2022 was Goldman Sachs, an estimated $147M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q2 2022 was Avidity Partners Management, an estimated $115M sold.
Based on aggregated 13F filings for Q2 2022.